BMJ Open

Association of liver enzymes levels with fasting plasma glucose levels in Southern China: a cross-sectional study

Ling-Ling Huang,1,2 Dong-Hui Guo,3 Hui-Yan Xu,4 Song-Tao Tang,5 Xiao Xiao Wang,1 Yong-Ping Jin,6 Peixi Wang1,7

ABSTRACT

Objective According to several studies, liver enzymes levels are associated with fasting plasma glucose (FPG) levels. However, the association stratified by body mass index (BMI) remains to be elucidated, especially in Southern China. Therefore, the aim of this study was to investigate the correlation between liver enzymes levels and FPG levels stratified by BMI in Southern China.

Design Cross-sectional study.

Participants and setting 3056 individuals participated in real-time interviews and blood tests in Southern China. Participants were divided into three groups (underweight, normal weight and overweight or obesity) based on BMI cut-offs.

Main outcome measured Partial correlation analysis was performed to investigate the relationship between FPG levels and liver tests. Multivariate logistic regression analyses were applied to calculate the adjusted ORs for FPG levels based on liver enzymes levels.

Results There was no association between liver enzymes and FPG either in the underweight group or in the normal weight group; however, a significant correlation was observed in the overweight or obesity group (alanine transaminase (ALT), p<0.01; aspartate aminotransferase (AST), p<0.05). After adjusting for confounding factors, the highest tertiles of ALT still remained significantly positively related to FPG levels in the overweight or obesity group, with an OR of 2.205 (95% CI 1.442 to 3.371) for the 5.56≤FPG<7.00 mmol/L group vs the FPG<5.56 mmol/L group and with an OR of 2.297 (95% CI 1.017 to 5.187) for the FPG≥7.00 mmol/L vs the FPG<5.56 mmol/L group, but this correlation was not found for AST.

Conclusions The association of liver enzymes levels with FPG levels differed based on different BMI cut-offs. ALT levels were significantly positively associated with FPG levels in the overweight or obesity group, but not in the other two groups; AST levels were not associated with FPG levels in any group.

INTRODUCTION

Diabetes, a prevalent chronic disease, has emerged as a major public health concern due to its increased prevalence in many countries, afflicting approximately 382 million people worldwide.1 China, the largest developing country, also has a high incidence of diabetes. Recently, a survey revealed that more than 1 in 10 Chinese adults were affected by diabetes.2 Therefore, the early identification of individuals at high risk of diabetes is essential for decreasing the prevalence of diabetes.

The liver is the site of glycogen synthesis and gluconeogenesis, which together with the pancreas, muscle, adipose tissue and other organs, plays an important role in maintaining the stable level of blood glucose.3 4 Liver enzymes, the most common markers of liver function in the clinic, include alanine transaminase (ALT) and aspartate aminotransferase (AST).5–7 Related studies suggested that the elevation of liver enzymes levels was indicative of insulin sensitivity reduction, insulin resistance and type 2 diabetes development.8–10 Fasting plasma glucose (FPG) is the most commonly used index to monitor the occurrence of early type 2 diabetes, which is of great significance in the prevention of diabetes. Although previous studies have reported that liver enzymes levels were significantly associated with FPG levels,3 10 11

Strengths and limitations of this study

A large sample of subjects was enrolled in this survey.

To the best of our knowledge, this is the first study to explore the correlation between liver enzymes levels and fasting plasma glucose (FPG) levels stratified by body mass index among people who had not been diagnosed with diabetes before this survey in Southern China.

The present study was designed as a cross-sectional study; therefore, direct causation cannot be concluded from the results.

Supplementary information about γ-glutamyltransferase levels, imaging studies, cholesterol and triglycerides was not collected; therefore, it could not be determined whether these factors were associated with FPG. Additionally, some factors such as cholesterol and triglycerides levels could not be adjusted in the multivariate logistic regression analyses.

To cite: Huang L-L, Guo D-H, Xu H-Y, et al. BMJ Open 2019;9:e025524. doi:10.1136/bmjopen-2018-025524

bmjopen-2018-025524

Supplementary information about γ-glutamyltransferase levels, imaging studies, cholesterol and triglycerides was not collected; therefore, it could not be determined whether these factors were associated with FPG. Additionally, some factors such as cholesterol and triglycerides levels could not be adjusted in the multivariate logistic regression analyses.
the evidence remained insufficient, because the reported results were inconsistent in terms of the population studied, such as populations from different regions and populations with different body mass indexes (BMIs). In addition, as we know, almost all related studies regarded BMI as only a covariate in the investigation of the relationship between liver enzymes levels and FPG levels in the general population, and few studies were conducted in Southern China. Therefore, the aim of this study was to determine the association of liver enzymes levels with FPG levels, stratified by BMI cut-offs (BMI was calculated as weight in kilograms divided by height metres squared). Individuals with a BMI<18.5 kg/m², 18.5–23.9 kg/m² or ≥24 kg/m² were categorised into the underweight group (n=141), the normal weight group (n=1788), and the overweight or obesity group (n=1127), respectively. Then, we stratified overweight and obese adults into three groups according to FPG levels: FPG<5.56 mmol/L, 5.56 ≤ FPG<7.00 mmol/L and FPG≥7.00 mmol/L. Each individual received written information about the aim of the study. If he/she decided to participate, a written informed consent was obtained.

MATERIALS AND METHODS

Study population

This cross-sectional study was conducted in the Guangdong Province of China in 2014. Initially, 3726 healthy inhabitants who underwent a general health examination (mean age: 60.32 years, ≥18 years old) were recruited from local Community Health Service Agencies. All participants completed the survey, and the overall response rate was 100%. The health examination included recording of general characteristics, medical history, anthropometric parameters and laboratory tests. After excluding subjects (n=574) with a history of diabetes, hepatitis B and all other liver diseases and subjects (n=96) with missing or invalid data on FPG levels or liver related indexes, 3056 eligible participants were included in the final analysis (figure 1). In addition, age and sex were compared between the excluded participants and those included in the final analysis, respectively, and there were no significant differences (table was presented in online supplementary file 1). Based on the basis of data from this study, subjects were classified into three groups (underweight, normal weight and overweight or obesity) based on BMI cut-offs (BMI was calculated as weight in kilograms divided by height metres squared). Individuals with a BMI<18.5 kg/m², 18.5–23.9 kg/m² or ≥24 kg/m² were categorised into the underweight group (n=141), the normal weight group (n=1788), and the overweight or obesity group (n=1127), respectively. Then, we stratified overweight and obese adults into three groups according to FPG levels: FPG<5.56 mmol/L, 5.56 ≤ FPG<7.00 mmol/L and FPG≥7.00 mmol/L. Each individual received written information about the aim of the study. If he/she decided to participate, a written informed consent was obtained.

General characteristics

Information on participants' demographic characteristics (age, sex, marital status and education level), health-related characteristics (physical activity, current smoking, alcohol consumption and BMI) and medical history (diabetes, hepatitis B and all other liver diseases) was included in the questionnaire. Marital status was categorised as ‘single’, ‘married’ and ‘divorce or widowed’. Education level was divided into four categories (no school, primary school, middle school and high school or above). Physical activity was categorised as ‘every day’, ‘more than once a week’, ‘seldom’ and ‘never’. Smoking status was categorised as ‘non-smoker’, ‘smoker’ and ‘ex-smoker’. Alcohol consumption was divided into three categories, ‘regularly’, ‘seldom’ and ‘never’. Smokers were defined as those who smoked one or more cigarettes per day for at least 6 months. Regular alcohol consumers were defined as those who consumed alcohol on average more than once a week within the last year. Additionally, because very few subjects were included in some dummy variables categories of marital status, education level, physical activity, current smoking and alcohol consumption, unmarried and divorced or widowed were considered single; no school and primary school were merged as primary school or below; physical activity (yes) included those who exercised every day or more than once a week; physical activity (no) included those who seldom or never exercised; non-smokers and ex-smokers were combined.
into current smoking (no); and alcohol consumption (yes) included those who regularly and seldom consumed alcohol.

**Anthropometric parameters and laboratory tests**

Anthropometric parameters (height and weight) were measured by trained staffs, following a standardised protocol. The data were collected in replicate, and mean values were calculated in the study. After overnight fasting (at least 8 hours), venous blood samples from participants were obtained and analysed by a PPI automatic biochemical analyzer (Roche Company, Germany) for FPG, albumin (ALB), direct bilirubin, indirect bilirubin (IBIL), total bilirubin, ALT and AST levels.

**Tertiles of liver enzymes levels**

Liver enzymes levels were categorised into tertiles based on individual distributions in the overweight or obesity group. ALT: Q1<17U/L, Q2=17–25U/L, Q3≥25U/L; AST: Q1<20U/L, Q2=20–24U/L, Q3≥24U/L.

**Procedures**

All data were collected on the same day via face-to-face interviews, and blood tests were performed by either a physician or a nurse (the healthcare staff from the local Community Health Service Agencies). The interviewers received training to improve their interview skills and standardise the procedures of data collection. In addition, several supervisors were selected to verify the authenticity of the data.

**Patient and public involvement**

The role of study subjects in our survey was participants. They were not involved in the development of the research question and outcome measures, the recruitment of subjects and the conduct of the study. After completing this survey, we sent each participant a letter describing detailed results of this study.

**Statistics analyses**

All statistical analyses were performed with the Statistical Package for the Social Sciences (SPSS) V.21.0 (SPSS, Chicago, Illinois, USA). Data are presented as the mean±SD and frequencies (percentage). A one-way analysis of variance (ANOVA) was conducted to evaluate differences in age and BMI according to FPG levels, and to test mean levels of FPG based on the tertiles of ALT and AST in the overweight or obesity group. The χ² test was used to compare the frequency of general characteristics (categorical variables) according to FPG levels in the overweight or obesity group. Partial correlation analysis was performed to investigate the relationship between BMI and related indexes among all participants, as shown in table 1, to determine the correlation between FPG levels and liver tests stratified by BMI, as shown in table 2. Multivariate logistic regression analyses were applied to calculate the adjusted ORs for FPG levels associated with liver enzymes levels in the overweight or obesity group (since there was no association between liver enzymes levels and FPG levels in underweight group and normal group, respectively, as shown in table 2, one-way ANOVA, χ² test and multivariate logistic regression were not performed for these two groups).

**RESULTS**

Of 3056 subjects, 50.3% (1537/3056) were found to have abnormal FPG levels, 22.9% (699/3056) had 5.56≤FPG<7.00 mmol/L and 5.5% (167/3056) had FPG≥7.00 mmol/L. Of 1127 overweight and obese adults,

| Table 1 | Partial correlation analysis between BMI and related indexes (n=3056) |
|---------------------------------|-------------------------------------------------------------|
| Related indexes | Partial correlation coefficient (controlling age, gender) | P value |
| FPG | 0.077 | <0.001*** |
| ALB | −0.010 | 0.573 |
| DBIL | −0.049 | 0.008** |
| IBIL | −0.004 | 0.833 |
| TBIL | −0.038 | 0.035* |
| ALT | 0.165 | <0.001*** |
| AST | 0.037 | 0.040* |

Except for gender, all the variables (age BMI, FPG, ALB, DBIL, IBIL, TBIL, ALT and AST) in the partial correlation coefficient were continuous variables. *P<0.05, **p<0.01, ***p<0.001.

| Table 2 | Partial correlation analysis between FPG levels and liver tests stratified by BMI (n=3056) |
|---------------------------------|-------------------------------------------------------------|
| Liver tests | Underweight group (correlation coefficient, n=141) | Normal weight group (correlation coefficient, n=1788) | Overweight or obesity group (correlation coefficient, n=1127) |
| ALB | −0.042 | −0.057* | −0.097** |
| DBIL | 0.021 | −0.024 | 0.033 |
| IBIL | −0.005 | −0.010 | −0.111*** |
| TBIL | −0.025 | −0.035 | −0.068* |
| ALT | 0.011 | 0.013 | 0.078** |
| AST | −0.034 | −0.039 | 0.070* |

Partial correlation coefficient: controlling age, gender and BMI. Except for sex, all the variables (age BMI, FPG, ALB, DBIL, IBIL, TBIL, ALT and AST) in the partial correlation analysis were continuous variables. *P<0.05, **p<0.01, ***p<0.001.

ALB, albumin; ALT, alanine transaminase; AST, aspartate aminotransferase; BMI, body mass index; DBIL, direct bilirubin; FPG, fasting plasma glucose; IBIL, indirect bilirubin; TBIL, total bilirubin.
34.0% (383/1127) were found to have abnormal FPG levels, 27.5% (310/1156) had FPG<7.00 mmol/L and 6.5% (73/1127) had FPG≥7.00 mmol/L.

**THE PARTIAL CORRELATION AND ONE-WAY ANOVA**

A total of 3056 adults were included in this study, comprising 141 (4.6%) individuals who were underweight, 1788 (58.5%) individuals with normal weight and 1127 (36.9%) individuals with overweight or obesity. The partial correlation coefficients between BMI and related indexes are shown in [table 1](#). Every index was significantly correlated with BMI, except for ALB and IBIL. Compared with other indexes, FPG and ALT were more strongly correlated with BMI.

Further, a partial correlation analysis was conducted to the relationship between FPG levels and liver tests stratified by BMI (shown in [table 2](#)). Notably, AST and ALT levels were not associated with FPG levels in the underweight group and normal weight group, respectively, but a significant association was observed in the overweight or obesity group. Of the two liver enzymes, ALT (r=0.097, p<0.05) was more strongly correlated with FPG levels than AST (r=0.070, p>0.05). The mean FPG levels by baseline tertiles of AST and ALT levels among overweight and obese adults are shown in [figure 2](#). The FPG levels were positively related to ALT levels (p<0.05), but not to AST levels (p>0.05).

**Association of general characteristics with FPG**

Mean age and BMI, and the frequency of sex, marital status, education level, physical activity, current smoking and alcohol consumption according to FPG levels in the overweight or obesity group are presented in [table 3](#). The mean ages were 60.01±12.67, 63.34±12.06 and 64.75±13.88 in the FPG<5.56 mmol/L, 5.56≤FPG<7.00 mmol/L and FPG≥7.00 mmol/L groups, respectively. Compared with the FPG<5.56 mmol/L group, the 5.56≤FPG<7.00 mmol/L and FPG≥7.00 mmol/L groups displayed significantly higher ages (p<0.05). The mean BMIs were 26.37±2.18, 26.65±2.21 and 26.92±2.59 in the FPG<5.56 mmol/L, 5.56≤FPG<7.00 mmol/L and FPG≥7.00 mmol/L groups, respectively. Compared with the FPG<5.56 mmol/L group, the FPG≥7.00 mmol/L group displayed a significantly higher BMI (p<0.05), but this was not true for the 5.56≤FPG<7.00 mmol/L group (p>0.05).

**Multivariate logistic regression analysis model**

The adjusted ORs for FPG levels associated with liver enzymes levels in the overweight or obesity group are listed in [table 4](#). Additionally, only those variables that were significantly correlated with FPG levels are presented in [table 4](#). After adjusting for potential confounders (age, BMI and liver tests), the highest tertiles of ALT levels remained significantly positively correlated with FPG levels with an OR of 2.205 (95% CI 1.442 to 3.371) for 5.56≤FPG<7.00 mmol/L vs FPG<5.56 mmol/L and with an OR of 2.297 (95% CI 1.017 to 5.187) for FPG≥7.00 mmol/L vs FPG<5.56 mmol/L, but this correlation was not found for AST.

Age had an OR of 1.024 (95% CI 1.013 to 1.036) for 5.56≤FPG<7.00 mmol/L vs FPG<5.56 mmol/L and of 1.033 (95% CI 1.012 to 1.054) for FPG≥7.00 mmol/L vs FPG<5.56 mmol/L. However, ALB levels displayed an OR of 0.951 (95% CI 0.928 to 0.982) for FPG≥7.00 mmol/L vs FPG<5.56 mmol/L.

**DISCUSSION**

Partial correlation analysis showed that AST and ALT levels were not associated with FPG levels in the underweight group and the normal weight group, but a significantly positive association of AST and ALT levels with FPG levels was observed in the overweight or obesity group ([table 2](#)). This positive association in the group of overweight or obese adults may be partly explained by the obesity-related diabetes. Fall and his colleagues found a causal effect of adiposity on ALT levels in a Mendelian randomisation analysis study. Mechanistically, increased intrahepatic fat content is bi-directionally associated with insulin resistance, which in turn can lead to increased glucose output from the liver.

In the current study, mean levels of FPG are shown in [figure 2](#) based on the baseline tertiles of AST and ALT levels in the overweight or obesity group. Our results revealed that the elevated FPG levels were related to the increased levels of liver enzymes, which is similar to the result of a recent study. Insulin resistance and reduced insulin sensitivity may be the key pathophysiological mechanism underlying this positive association between liver enzymes levels and FPG levels. An epidemiological study conducted with 10800 middle-aged participants noted that elevated liver enzymes levels were closely related to insulin resistance. Bonnet et al found that liver enzymes activities, even within the normal range,
can reduce hepatic insulin extraction among healthy men and women.9

In regard to the identification of liver injury, ALT is more specific than AST.18 For instance, Mainous et al., in the analysis of a nationally representative sample of the non-institutionalised US population, found that ALT levels, but not AST levels, were independently linked with undiagnosed diabetes (defined as FPG≥126 mg/dL) as well as impaired fasting glucose (defined as 100≤FPG≤125 mg/dL),19 which is consistent with our results in general. In our study, after adjusting for potential confounders (age, BMI and liver tests), ALT levels remained significantly positively correlated with FPG levels both for 5.56≤FPG<7.00 mmol/L vs FPG<5.56 mmol/L.

### Table 3  General characteristics associated with FPG levels in the overweight or obesity group (n=1127)

| Variables                  | FPG<5.56 (n=744) | 5.56≤FPG<7.00 (n=310) | FPG≥7.00 (n=73) |
|----------------------------|------------------|-----------------------|-----------------|
| Age, years (m, SD)         | 60.01±12.67      | 63.34±12.06*          | 64.75±13.88**   |
| Sex (n, %)                 |                  |                       |                 |
| Male                       | 255 (34.4)       | 106 (34.2)            | 35 (47.9)       |
| Female                     | 489 (65.7)       | 204 (65.8)            | 38 (52.1)       |
| Marital status (n, %)      |                  |                       |                 |
| Single                     | 82 (11.4)        | 23 (7.7)              | 10 (14.7)       |
| Married                    | 635 (88.6)       | 275 (92.3)            | 58 (85.3)       |
| Education level (n, %)     |                  |                       |                 |
| Primary school or below    | 161 (37.9)       | 86 (43.0)             | 18 (38.3)       |
| Middle school              | 221 (52.0)       | 91 (45.5)             | 25 (53.2)       |
| High school or above       | 43 (10.1)        | 23 (11.5)             | 4 (8.5)         |
| Physical activity (n, %)   |                  |                       |                 |
| Yes                        | 202 (27.2)       | 101 (32.6)            | 21 (28.8)       |
| No                         | 542 (72.8)       | 209 (67.4)            | 52 (71.2)       |
| Current smoking (n, %)     |                  |                       |                 |
| Yes                        | 33 (4.4)         | 15 (4.8)              | 8 (11.0)        |
| No                         | 711 (95.6)       | 295 (95.2)            | 65 (89.0)       |
| Alcohol consumption (n, %) |                  |                       |                 |
| Yes                        | 13 (1.7)         | 9 (2.9)               | 3 (4.1)         |
| No                         | 731 (98.3)       | 301 (97.1)            | 70 (95.9)       |
| BMI, kg/m² (m, SD)         | 26.37±2.18       | 26.65±2.21            | 26.92±2.59**    |

Data are presented as the mean (SD) or n (%). Single: unmarried, divorced or widowed; primary school or below: no school, primary school; physical activity (yes): every day, more than once a week; physical activity (no): seldom, never; current smoking (no): non-smoker, ex-smoker; alcohol consumption (yes): regularly, seldom.

*P<0.05 5.56≤FPG<7.00 mmol/L vs FPG<5.56 mmol/L; **p<0.05 FPG≥7.00 mmol/L vs FPG<5.56 mmol/L.

BMI, body mass index; FPG, fasting plasma glucose.

### Table 4  ORs for FPG elevation by liver enzymes levels in the overweight or obesity group (n=1127)

| Variables | 5.56≤FPG<7.00 vs FPG<5.56 |          | FPG≥7.00 vs FPG<5.56 |          |
|-----------|---------------------------|----------|----------------------|----------|
|           | OR (95% CI)                | P value  | OR (95% CI)          | P value  |
| Age       | 1.024 (1.013 to 1.036)     | <0.001***| 1.033 (1.012 to 1.054)| 0.002**  |
| ALB       |                           |          | 0.954 (0.928 to 0.982)| 0.001**  |
| ALT Q1    | Reference                 |          |                      |          |
| Q2        | 1.357 (0.936 to 1.967)     | 0.108    | 1.677 (0.799 to 3.516)| 0.171    |
| Q3        | 2.205 (1.442 to 3.731)     | <0.001***| 2.297 (1.017 to 5.187)| 0.045*   |

Statistical analysis by multivariate logistic regression (adjusted for age, BMI and liver tests).

Goodness-of-fit results: Pearson χ² test, p=0.465; Deviance χ² test, p=1.000.

ALB, albumin; ALT, alanine transaminase.; BMI, body mass index; FPG, fasting plasma glucose.
Land FPG≥7.00 mmol/L vs FPG<5.56 mmol/L, but this correlation was not found for AST. An explanation may be that ALT predominantly exists in liver, whereas AST is found in the liver and also in cardiac and skeletal muscle, the brain and other organs. ALT is the most closely related one to liver fat content. Liver fat content, except under certain conditions, has been reported to be linked with insulin resistance. In addition, Xu et al clarified that the effect of AST levels on diabetes risk was partly due to ALT levels. In addition to ALT and AST, γ-glutamyltransferase (GGT) is also a liver enzyme. Currently, the association between GGT levels and FPG levels remains controversial. Recent literature has reported that a moderate elevation between GGT levels and FPG levels remains controversial. (GGT) is also a liver enzyme. Currently, the association of liver enzymes levels with FPG levels remains controversial. In addition, the highest tertiles of ALT levels were associated with a more than twofold increase in FPG levels (for 5.65≤FPG<7.00 mmol/L vs FPG≤5.56 mmol/L) among overweight or obese individuals, independent of conventional risk factors. In depth, the highest tertiles of ALT levels were more significantly correlated with FPG levels for FPG≥7.00 mmol/L vs FPG<5.56 mmol/L (table 4), which was similar to the result of an early study. Yu et al reported that compared with normal ALT levels, the relative risk for the incidence of impaired fasting glucose (100≤FPG≤125 mg/dL) and diabetes (FPG≥126 mg/dL) based on the level of ALT was 3.09 for borderline elevated ALT levels and 1.59 for elevated ALT levels. NAFLD may play an important role in the relationship between ALT levels and FPG levels among overweight or obese individuals. It has been found that patients with NAFLD are at increased risk for developing type 2 diabetes. Liver fat content was inversely associated with hepatic, adipose tissue and muscle insulin sensitivity, which might contribute to the increased risk of type 2 diabetes. Additionally, NAFLD can result in an elevated ALT levels. The following mechanisms may also be regarded as the underlying causes of the association between elevated ALT levels and the increased risk of elevated FPG levels. (1) Elevated ALT levels reflected potential chronic inflammation and increased oxidative stress, and chronic inflammation and oxidative stress appeared to be involved in the pathogenesis of NAFLD, which may impair insulin signalling in the liver and other organ tissues. (2) Elevated ALT levels could reflect life-long hepatitis virus infection, which can result in diabetes. (3) Testosterone levels may be the mediator between ALT levels and the risk of diabetes. Researchers have revealed the role of low testosterone in diabetes, and that poor liver function may reduce testosterone production.

Our study was conducted in Community Health Service Agencies, in Guangdong Province of China, which may imply that the generalisability of our results is limited to this region. Additionally, participants with a history of diabetes, hepatitis B or other liver diseases were excluded from the study, so our results are not applicable to these subjects.

In addition to GGT not being included in this study, the limitations of the current study included the absence of imaging studies. Recent studies have noted that imaging studies will likely provide a new opportunity for investigating the association of the liver function with diabetic disease. Then, online supplementary information about the blood lipids, disease types and medication history of subjects was not collected. Hence, some factors such as cholesterol and triglyceride levels, could not be included as covariates in our multivariate logistic regression analyses. In addition, our study design was cross-sectional, and direct causation cannot be concluded from these results.

CONCLUSION
The association of liver enzymes levels with FPG levels differed based on a BMI cut-off. ALT levels were significantly positively associated with FPG levels in the overweight or obesity group, but not in the underweight group and normal weight groups; AST levels were not associated with FPG levels in any group. These findings have important clinical implications for health policy makers. Liver enzymes may serve as effective indexes for the early detection of individuals at high risk of diabetes on a BMI-dependent basis.

Author affiliations
1School of Nursing and Health, Chronic Disease Risks Assessment, Henan University, Kaifeng, China
2School of Nursing and Health, Lida University, Shanghai, China
3Community Health Management Center, People’s Hospital of Longhua New District, Shenzhen, China
4Community Health Services Center of Liwan, Guangzhou, China
5Community Health Services Center of Liubu, Dongguan, China
6School of Nursing and Health, Institute of Laboratory, Henan University, Kaifeng, China
7General Practice Center, Nanhai Hospital, Southern Medical University, Foshan, China

Acknowledgements We gratefully acknowledge the staff of the local Community Health Service Agencies for their kind assistance in data collection and other people who assisted us throughout the study.

Contributors L-LH, Y-PJ and PW conducted the data analyses. L-LH and D-HG drafted the manuscript. D-HG, H-YX, S-TT and XXW finalised the manuscript with inputs from all authors. All authors contributed to the development of the study framework, interpretation of the results and revisions of successive drafts of the manuscript and approved the version submitted for publication.

Funding This study was supported by the Medical Scientific Research Foundation of Guangdong Province (C2015032) and the Medical Scientific and Technological Research Foundation of Guangdong Province (C2015019).

Huang L-L, et al. BMJ Open 2019;9:e025524. doi:10.1136/bmjopen-2018-025524
REFERENCES

1. International Diabetes Federation. *IDF diabetes atlas sixth edition*. Brussels, Belgium: International Diabetes Federation, 2013.
2. Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults. *JAMA* 2013;310:948–59.
3. Qin G, Lu L, Xiao Y, et al. A cross-sectional study of the relationship between serum liver enzymes level and the incidence of impaired fasting glucose in males and females. *Med Sci Monit* 2014;20:1319–25.
4. Sun Q, Cornelis MC, Manson JE, et al. Plasma levels of fetuin-A and hepatic enzymes and risk of type 2 diabetes in women in the U.S. *Diabetes* 2013;62:49–55.
5. Kunutsor SK, Apokey TA, Walley J. Liver aminotransferases and risk of incident type 2 diabetes: a systematic review and meta-analysis. *Am J Epidemiol* 2013;178:159–71.
6. Cho NH, Jiang HC, Choi SH, et al. Abnormal liver function test predicts type 2 diabetes: a community-based prospective study. *Diabetes Care* 2007;30:2566–8.
7. Kim HC, Kang DR, Nam CM, et al. Elevated serum aminotransferase level as a predictor of intracerebral hemorrhage: Korea medical insurance Corporation study. *Stroke* 2005;36:1642–7.
8. Huang J, Karnchanasorn R, Ou H-Y, et al. Association of insulin resistance with serum fetuin and aminotransferases-iron hypothesis. *World J Exp Med* 2015;5:232–43.
9. Bonnet F, Ducluzeau P-H, Gастaldielli A, et al. Liver enzymes are associated with hepatic insulin resistance, insulin secretion, and gluconac concentration in healthy men and women. *Diabetes* 2011;60:1660–7.
10. Lee K, Han J, Kim S-G. Increasing risk of diabetes mellitus according to liver function alterations in electronic workers. *J Diabetes Investig* 2014;5:671–6.
11. Hong Z, Yang J, Shurell H, et al. Relationship between serum aminotransferase levels and metabolic disorders in northern China. *Turk J Gastroenterol* 2012;23:699–707.
12. Huang LL, Dou D-M, Liu N, et al. Association of erythrocyte parameters with metabolic syndrome in the pear River delta region of China: a cross sectional study. *BMJ Open* 2018;8:e018792.
13. Fall T, Hägg S, Mägi R, et al. The role of adiposity in cardiometabolic traits: a Mendelian randomization analysis. *PLoS Med* 2013;10:e1001474.
14. Londero A, Ballestri S, Marchesini G, et al. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. *Dig Liver Dis* 2015;47:181–90.
15. Ballestri S, Nacsimbeni F, Romagnoli D, et al. The independent predictors of non-alcoholic steatohepatitis and its individual histological features.: insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment. *Hepatol Res* 2016;46:1074–87.
16. Chen S, Guo X, Yu S, et al. Metabolic syndrome and serum liver enzymes in the general Chinese population. *Int J Environ Res Public Health* 2016;13:2339.
17. Xie J-H, Liu Q, Yang Y, et al. Correlation of liver enzymes with diabetes and pre-diabetes in middle-aged rural population in China. *J Huazhong Univ Sci Technolog Med Sci* 2016;36:53–8.
18. Ruhl CE, Everhart JE. Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. *Gastroenterology* 2009;136:477–85.
19. Mainous AG, Diaz VA, King DE, et al. The relationship of hepatitis antibodies and elevated liver enzymes with impaired fasting glucose and undiagnosed diabetes. *J Am Board Fam Med* 2008;21:497–503.
20. Westerbacka J, Cornèr A, Tilkikainen M, et al. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. *Diabetologia* 2004;47:1360–9.
21. Stefan N, Häring H-U. The metabolically benign and malignant fatty liver. *Diabetes* 2011;60:2011–7.
22. Xu L, Jiang CQ, Schooling CM, et al. Liver enzymes and incident diabetes in China: a prospective analysis of 10 764 participants in the Guangzhou Biobank Cohort Study. *J Epidemiol Community Health* 2015;69:1040–4.
23. Gautier A, Balkau B, Lange C, et al. Risk factors for incident type 2 diabetes in individuals with a BMI of &lt;27 kg/m2: the role of gamma-glutamyltransferase. Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). *Diabetologia* 2010;53:247–53.
24. Fraser A, Harris R, Sattar N, et al. Alanine Aminotransferase, -Glutamyltransferase, and Incident Diabetes: The British Women’s Heart and Health Study and meta-analysis. *Diabetes Care* 2009;32:741–50.
25. Oka R, Aizawa T, Yagi K, et al. Elevated liver enzymes are related to progression to impaired glucose tolerance in Japanese men. *Diabetic Medicine* 2014;31:552–8.
26. Ballestri S, Zona S, Targher G, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. *J Gastroenterol Hepatol* 2016;31:936–44.
27. Nguyen QM, Sinivasan SR, Xu J-H, et al. Elevated liver function enzymes are related to the development of prediabetes and type 2 diabetes in younger adults: the Bogalusa heart study. *Diabetes Care* 2011;34:2603–7.
28. Yu J-H, Kim J-S, Lee M-R, et al. Risks of borderline liver enzyme abnormalities to the incidence of impaired fasting glucose and diabetes mellitus: a 7 year follow up study of workers. *Ann Occup Environ Med* 2016;28.
29. Tziomalos K, Athyros VG, Karagiannis A. Non-Alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options. *Curr Vasc Pharmacol* 2012;10:162–72.
30. Herder C, Peltonen M, Koenig W, et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish diabetes prevention study. *Diabetes* 2016;65:2340–6.
31. Gautam D, Hemant B. Hepatitis C virus infection and diabetes. *Pract Diabet* 2016;33:123–8.
32. Corona G, Monami M, Rastrelli G, et al. Testosterone and metabolic syndrome: a meta-analysis study. *J Sex Med* 2011;8:272–83.
33. Nitsche R, Coelho JCU, Freitas ACTde, et al. Testosterone changes in patients with liver cirrhosis before and after orthotopic liver transplantation and its correlation with MELD. *Ang Gastroenterol* 2014;51:59–63.
34. Londero A, Nacsimbeni F, Targher G, et al. ALSF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future direction. *Dig Liver Dis* 2017;50:1928–9.
35. Ballestri S, Romagnoli D, Nacsimbeni F, et al. Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. *Expert Rev Gastroenterol Hepatol* 2015;9:603–27.

Huang L-L, et al. *BMJ Open* 2019;9:e025524. doi:10.1136/bmjopen-2018-025524